Clinical trials: Hematologic and Lymphocytic Disorder
Iron Deficiency Anemia, Iron-deficiency
Multiple Daily Condensed Tannin Supplementation and Iron Bioavailability: The Tannin Dose Response Trial
Tannins are known to inhibit iron absorption through formation of insoluble tannin-mineral complexes, and have thus been termed 'antinutritional.' Despite this, there is evidence that adaptation to similar antinutritional factors…
- Trial name
- NCT03030716
- Testing
- 95% condensed proanthocyanidins from grape seed extract
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Kansas State University
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory).
- Conditions
- Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT03683433
- Testing
- Azacitidine, Enasidenib Mesylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
This phase II trial studies how well sotrastaurin acetate works in treating patients with chronic lymphocytic leukemia, small lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation that has returned or that…
- Conditions
- Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
- Trial name
- NCT02285244
- Testing
- sotrastaurin acetate, pharmacological study, laboratory biomarker analysis
- Sponsor
- James Blachly
Fetomaternal Transfusion
Effect of Placental Drainage of Fetal Blood at Cesarean Section on the Incidence of Feto-Maternal Transfusion
Study hypothesis: umbilical cord drainage of fetal blood after delivery of the infant would reduce the incidence of feto-maternal transfusion.
- Trial name
- NCT00470899
- Testing
- drainage of placenta of fetal blood
- Volunteers
- 86 people
- Sponsor
- Lester E. Cox Medical Centers
Anemia
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis.
This 2 arm study will compare the hemoglobin maintenance with once monthly methoxy polyethylene glycol-epoetin beta (Mircera) administration versus epoetin beta or darbepoetin alfa in participants with chronic kidney disease on…
- Trial name
- NCT00717821
- Testing
- Methoxy Polyethylene Glycol-epoetin Beta, Epoetin Beta, Darbepoetin Alfa
- Where
- 89 sites in France
- Volunteers
- 421 people
- Sponsor
- Hoffmann-La Roche
Cancer, Anemia
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
The purpose of this study is to determine the effectiveness and safety of PROCRIT (Epoetin alfa) at a starting dose of 60,000 Units (U) once every week (QW) to a target hemoglobin (Hb) of 12 g/dL (Initiation Phase), followed by a…
- Trial name
- NCT00338416
- Testing
- Epoetin alfa
- Volunteers
- 115 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Coagulation Disorder, Cirrhosis, Liver
ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension
Hemostasis-related disorders are common in cirrhosis and portal hypertension. However, it is not known whether the net effect of changes in hemostasis in the sense of predisposition to hemorrhagic or thrombotic state.
- Trial name
- NCT04267406
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Schistosomiasis, Anemia
Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal
SchistoVAN aims to study the role of schistosomiasis infection in the modulation of the immune response of children to childhood vaccine antigens, as well as the impact of this infection on their nutritional status and their…
- Conditions
- Schistosomiasis, Anemia, Underweight, Stunting
- Trial name
- SchistoVAN (NCT01553552)
- Where
- Senegal
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Biomedical Research Center EPLS
Advanced Lymphoma, Refractory Lymphoma
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice
- Conditions
- Advanced Lymphoma, Refractory Lymphoma, Refractory Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- EXALT-2 (NCT04470947)
- Testing
- Next generation functional drug screening, Comprehensive genomic profiling
- Where
- Austria
- Volunteers
- 150 people
- Sponsor
- Medical University of Vienna
Paroxysmal Nocturnal Hemoglobinuria
rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study
Long term management of patients with complement related diseases including Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome
- Trial name
- CONSERVE (NCT03829449)
- Testing
- rVA576
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- AKARI Therapeutics
Leukemia, Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004858
- Testing
- B43-genistein immunoconjugate
- Where
- 3 sites in United States
- Sponsor
- Parker Hughes Cancer Center
Multiple Myeloma, Melanoma
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
- Conditions
- Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
- Trial name
- NCT03399448
- Testing
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Leukemia
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes
The goal of this clinical research study is to find the highest tolerable dose of OPB-31121 that can be given to patients with leukemia or myelodysplastic syndrome (MDS).
- Trial name
- NCT01029509
- Testing
- OPB 31121
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia (AML)
A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia
This randomized, open label, multi arm phase II trial will evaluate the efficacy and safety of venetoclax based induction regimens of varying intensity (VA, VAM, or 2+5+V) versus standard 3+7 in fit patients aged ≥14 years with…
- Trial name
- NCT07754799
- Testing
- Daunorubicin, Cytarabine, Liposome Mitoxantrone
- Volunteers
- 320 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants
The purpose of this study is to describe contemporary, real-world patterns of participant characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in participants with newly diagnosed [ND]…
- Trial name
- NCT02761187
- Testing
- No Intervention
- Where
- 137 sites in United States, Belgium and 13 more
- Volunteers
- 4,253 people
- Sponsor
- Takeda
Complement Mediated Diseases
First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers
Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the complement inhibitor AMY-101.
- Trial name
- NCT03316521
- Testing
- AMY-101
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amyndas Pharmaceuticals S.A.
Acute Myeloid Leukemia
Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common…
- Trial name
- ICAML2015 (NCT03023384)
- Where
- 6 sites in Brazil
- Volunteers
- 547 people
- Sponsor
- International Consortium on Acute Leukemias
Anemia
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).
- Trial name
- NCT02912533
- Testing
- JR-131
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Multiple Myeloma
BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma
This is a prospective, non-inferiority study comparing VRD±D followed by BCMA CAR-T cell therapy versus VRD±D followed by autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma…
- Trial name
- CAREMM-006 (NCT06793449)
- Testing
- anti-BCMA CAR-T, ASCT
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.